MiNK Therapeutics, Inc.

INKT

$11.23

-0.88%

2026-09-03 16:00:00 EDT-$0.10

Healthcare

Biotechnology

NASDAQ

Active Trading

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction ...

Price Action of INKT

$11.23

-0.88%-$0.10

High—

Low—

52W High-33.9%

Rel. vol—

Interval

Range4.1h

Volume—SMA5SMA10

—

MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic, off-the-shelf iNKT cell therapies. Founded in 2017 (previously AgenTus Therapeutics, and renamed in June 2021), the company is headquartered in New York City and operates as a subsidiary of Agenus Inc. The company's lead candidate, ...MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic, off-the-shelf iNKT cell therapies. Founded in 2017 (previously AgenTus Therapeutics, and renamed in June 2021), the company is headquartered in New York City and operates as a subsidiary of Agenus Inc. The company's lead candidate, AGENT-797, is an allogeneic iNKT cell therapy currently in Phase 1 clinical trials for multiple myeloma. iNKT cells are a unique immune cell type that bridges innate and adaptive immunity, offering potential advantages in treating cancers and immune disorders. MiNK's platform aims to provide readily available, off-the-shelf treatments, overcoming the limitations of personalized cell therapies. As of the latest data, the company has a small team of 15 full-time employees, reflecting its early-stage status. Financially, the company has no revenue and is investing heavily in R&D, leading to negative earnings and cash flow metrics (e.g., net income per share of -$2.599). Key financials include a market cap of ~$55.9 million, low beta of 0.482, and no dividends. The company's leadership is headed by CEO Dr. Jennifer Buell, PhD, who has extensive experience in biotech. MiNK is dedicated to advancing its pipeline, and its future hinges on successful clinical trials and regulatory approvals.ExpandCollapse

Founded

2017

Employees

CEO

Jennifer S. Buell

Full Name

MiNK Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

83.45%

Market Cap

$0.06B

Current Ratio

1.23

WACC

6.57%

ROIC

-559.88%

Contact Information

https://minktherapeutics.com

212 994 8250

149 Fifth Avenue, New York City, NY 10010

Key Metrics of INKT

Snapshot

Latest / TTM · 6 periods

Market Cap

$55.95M

ROCE

-604.2%

EV / EBITDA

-4.18x

+430.0% YoY

FCF Yield

-3731.3%

-3718.9% YoY

Cash Conversion Cycle

-9267.0d

Current Ratio

1.23

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of INKT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-4.70x

n/a

Debt / Equity

0.00

n/a

Current Ratio

1.23

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of INKT

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.35 · Revenue $1.60M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.39 · Revenue $1.80M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-2.48 · Revenue $3.40M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-1.13 · Revenue $0.00 · 1 analysts

Recent history

Aug 13, 2026
Q2 FY2026 · Results reported
EPS $-0.62 · Revenue $0.00
View filing
May 15, 2026
Q1 FY2026 · Results reported
EPS $-0.57 · Revenue $0.00
View filing
Mar 31, 2026
FY2025 · Annual results
EPS $-2.93 · Revenue $0.00
View filing
Nov 14, 2025
Q3 FY2025 · Results reported
EPS $-0.65 · Revenue $0.00
View filing
Aug 14, 2025
Q2 FY2025 · Results reported
EPS $-1.06 · Revenue $0.00
View filing
May 15, 2025
Q1 FY2025 · Results reported
EPS $-0.70 · Revenue $0.00
View filing

Financial Statements of INKT

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-12.5M	-15.9%	-14.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-5.9M	+38.0%	-120113.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-36.4%	-44.8%	—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.06x	+48.3%	-10.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$14.2M	+148.9%	-7.3%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-2.93 vs -3.07	+4.6%	-0.62 vs -0.60	-3.3%
Revenue Surprise	—	—	—	—

Insider Transactions of INKT

Acquisitions (A)

Since Jun 1, 2026

Disposals (D)

Since Jun 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	WIINBERG ULF	director	Common Stock	A	1,279	$10.95
Sep 1, 2026	Holcomb John Bradley	director	Common Stock	A	1,233	$10.95
Sep 1, 2026	Behner Peter	director	Common Stock	A	1,485	$10.95
Sep 1, 2026	Ryan Barbara	director	Common Stock	A	1,622	$10.95
Sep 1, 2026	Corvese Brian	director	Common Stock	A	1,633	$10.95

Earnings Call Transcript of INKT

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning and welcome to MiNK Therapeutics' second quarter 2026 conference call and webcast. All participants will be in a listen-only mode until the question and answer session. Please note this event is being recorded. I would now like to turn the conference over to Stefanie Perna-Nacar from MiNK Therapeutics, MiNK Investor Relations. Stephanie, please go ahead. Stefanie Perna-Nacar: Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Dr. Terese Hammond, Head of Development, and Melissa Orilall, Principal Financial Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Dr. Buell? Jennifer Buell: Thank you, Stephanie. Good morning, and thank you for joining us. The second quarter was an important period of execution for MiNK. We moved agenT-797 into a randomized phase two study in patients with acute lung injury and ARDS. We presented initial day 28 observations from treated patients and establish our 1st, international paid named patient access program. Together, these reflect the model we are building, rigorous clinical development, rapid delivery of an off-the-shelf cell therapy, and responsible access for patients with urgent unmet needs. Critical illness is still treated largely by supporting failing organs while clinicians wait for the underlying injury to resolve. Ventilators support the lungs. Vasopressors support the circulation. Antibiotics address infection. There remained no approved pharmacologic therapy shown to reduce mortality in patients with ARDS or to restore coordinated immune function after severe lung injury. More than half of the patients with ARDS succumb to their disease and die. Our thesis is that this is fundamentally a problem of immune regulation. Patients with severe hypoxemic respiratory failure die because the host responds to the insult destroys the lungs, the epithelium, the endothelium, the barrier. What has been tried in this indication has largely either suppressed immunity globally, such as corticosteroids do, or stimulated it, but neither restores regulation. Invariant natural killer T cells are a regulatory T cell population. They sit at the interface of innate and adaptive immunity and they read the tissue environment that they are placed into and they direct the responses accordingly. HN797 is an allogeneic off-the-shelf invariant natural killer T cell product, it's designed to address several linked features …

Leadership Team of INKT

5 executives

Name	Title	Compensation	Gender	Year Born	Status
Jennifer S. Buell	Co-Founder, President, CEO & Director	USD 803,686	—	1975	Active
Terese C. Hammond	Head of Inflammatory & Pulmonary Diseases	—	Female	—	Active
Melissa Orilall	Principal Financial Officer	—	Female	1989	Active
Garo H. Armen	Executive Chairman	—	—	1953	Active
Austin Charette	Principal Accounting Officer	—	Male	1989	Active

Recent News of INKT

Seeking Alpha8/13/2026Neutral

MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript

MarketBeat8/13/2026Neutral

MiNK Therapeutics Q2 Earnings Call Highlights

MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.

GlobeNewsWire8/13/2026Neutral

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.

GlobeNewsWire8/6/2026Neutral

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK's off-the-shelf allogeneic iNKT cell therapy, in acute lung injury.

Zacks Investment Research7/16/2026Neutral

Here's Why You Should Add INKT Stock to Your Portfolio Now

MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.

Historical Employee Count of INKT

Current

Change

-34.78%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	15	10-K	Mar 31, 2026	View
Dec 31, 2024	23	10-K	Mar 18, 2025	View
Dec 31, 2023	31	10-K	Mar 21, 2024	View
Dec 31, 2022	37	10-K	Mar 24, 2023	View
Dec 31, 2021	33	10-K	Mar 18, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

MiNK Therapeutics, Inc.